Nyrada Inc. (ASX:NYR)

Market Cap	63.44M
Revenue (ttm)	1.65M
Net Income (ttm)	-3.99M
Shares Out	211.46M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	829,747
Average Volume	616,383
Open	0.3000
Previous Close	0.3000
Day's Range	0.2900 - 0.3000
52-Week Range	0.0320 - 0.3700
Beta	0.78
RSI	48.46
Earnings Date	Aug 22, 2025

About Exscientia

Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. Its develops oral Proprotein Convertase Subtilisin/Kexin Type 9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs; and neuroprotectant drug to reduce long-term disability in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Country: United States
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: NYR

Financial Performance

In 2024, Nyrada's revenue was 3.24 million, an increase of 126.72% compared to the previous year's 1.43 million. Losses were -1.39 million, -82.12% less than in 2023.

Financial numbers in EUR